FORT LAUDERDALE, Fla. and BUDAPEST, Hungary, Sept. 6, 2016 /PRNewswire/ -- ECHNO Conference -- Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced a presentation of data related to studies conducted to better understand the performance characteristics of a combined salivary CD44 and total protein assay in the diagnosis of head and neck squamous cell carcinoma (HNSCC). The studies provided direction for the clinical development of Vigilant Biosciences OncAlert™ Oral Cancer and OncAlert™ Labs product lines.
The study, titled, "Multivariate models which include oral rinse CD44 and total protein levels combined with clinical variables accurately predicts head and neck squamous cell carcinoma," was based on previous proof-of-concept studies conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, which demonstrated the ability to identify the presence of the tumor-initiating and stem cell-associated biomarker CD44, together with total protein, to indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms, by using a simple, oral rinse procedure.
The data will be presented at the 7th European Conference on Head and Neck Oncology (ECHNO), which will be held September 7-10, 2016, in Budapest, Hungary.
Details for the poster session are as follows:
Title: "Multivariate models which include oral rinse CD44 and total protein levels combined with clinical variables accurately predicts Head and neck squamous cell carcinoma (HNSCC)"
Presenter: Michael Donovan, Ph.D., M.D., Chief Clinical Officer
Presentation Number: 0453
The poster will be displayed at the conference venue throughout the length of the conference.
The full schedule of events can be viewed at echno2016.org.
ECHNO, the biannual congress of the European Head and Neck Society, has become the leading forum for presenting the latest and innovating research, both basic and clinical, in the field of head and neck oncology in Europe.
These studies were conducted by the Department of Public Health Sciences and Division of Biostatistics, University of Miami, Miami, Florida; Vigilant Biosciences, Ft. Lauderdale, Florida; the Department of Pathology, Icahn School of Medicine at Mt. Sinai, New York City, New York; the Department of Otolaryngology, University of Miami, Miami, Florida; and the Department of Pathology, Icahn School of Medicine at Mt. Sinai, New York City, New York.
About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlertTM Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMarkTM Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vigilant-biosciences-announces-poster-presentation-on-measuring-cd44-and-total-protein-levels-to-predict-head-and-neck-squamous-cell-carcinoma-at-7th-european-conference-on-head-and-neck-oncology-300322669.html
SOURCE Vigilant Biosciences, Inc.